Somatrogon

Somatrogon is a long-acting recombinant human growth hormone-CTP (carboxy-terminal peptide) fusion protein for once-weekly treatment of pediatric growth hormone deficiency, created by fusing human GH with three CTP sequences from human chorionic gonadotropin beta-subunit. The CTP extensions reduce renal clearance and extend the half-life, enabling less frequent dosing while maintaining full GH receptor agonist activity. It provides equivalent growth-promoting effects to daily GH therapy with improved convenience.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Somatrogon is an approved drug. It has reached clinical phase 4. It is classified as a Protein.